{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:24:23Z","timestamp":1790227463143,"version":"4.1.0"},"reference-count":176,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1016\/j.pharmthera.2005.03.009","type":"journal-article","created":{"date-parts":[[2005,6,14]],"date-time":"2005-06-14T07:25:33Z","timestamp":1118733933000},"page":"180-192","source":"Crossref","is-referenced-by-count":86,"title":["The platelet P2 receptors as molecular targets for old and new antiplatelet drugs"],"prefix":"10.1016","volume":"108","author":[{"given":"Christian","family":"Gachet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2005.03.009_bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0165-6147(02)00038-X","article-title":"Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family","volume":"24","author":"Abbracchio","year":"2003","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tips.2004.10.010","article-title":"The recently deorphanized GPR80 (GPR99) proposed to be the P2Y15 receptor is not a genuine P2Y receptor","volume":"26","author":"Abbracchio","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1538-7836.2004.01063.x","article-title":"Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases","volume":"3","author":"Aleil","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib4","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI17864","article-title":"P2Y12 regulates platelet adhesion\/activation, thrombus growth, and thrombus stability in injured arteries","volume":"112","author":"Andre","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib5","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1161\/01.CIR.0000093279.36628.12","article-title":"Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis","volume":"108","author":"Andre","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1517\/14728214.8.1.93","article-title":"ADP receptor antagonists as antiplatelet therapeutics","volume":"8","author":"Bauer","year":"2003","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1527-3466.2003.tb00106.x","article-title":"The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179","volume":"21","author":"Baurand","year":"2003","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib8","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1055\/s-0037-1614049","article-title":"Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors","volume":"84","author":"Baurand","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0014-2999(01)00733-6","article-title":"Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist","volume":"412","author":"Baurand","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib10","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1124\/mol.104.004846","article-title":"Differential regulation and relocalization of the platelet P2Y receptors after activation: a way to avoid loss of hemostatic properties?","volume":"67","author":"Baurand","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","article-title":"Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)","volume":"102","author":"Bertrand","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib12","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1124\/mol.64.5.1210","article-title":"Purification and functional reconstitution of the human P2Y12 receptor","volume":"64","author":"Bodor","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/194927b0","article-title":"Aggregation of blood platelets by adenosine diphosphate and its reversal","volume":"194","author":"Born","year":"1962","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1161\/01.CIR.72.4.741","article-title":"Adenosine diphosphate as a mediator of platelet aggregation in vivo: an editorial view","volume":"72","author":"Born","year":"1985","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib15","article-title":"Development of novel and reversible antagonists of P2Y12 receptors as antithrombotic drugs (abstract)","author":"Boyer","year":"2004"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib16","first-page":"1323","article-title":"Identification of competitive antagonists of the P2Y1 receptor","volume":"50","author":"Boyer","year":"1996","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0701837","article-title":"Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2\u2032- deoxyadenosine 3\u2032,5\u2032-bisphosphate","volume":"124","author":"Boyer","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib18","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1038\/sj.bjp.0704673","article-title":"2-Chloro N(6)-methyl-(N)-methanocarba-2\u2032-deoxyadenosine-3\u2032,5\u2032-bisphosphate is a selective high affinity P2Y(1) receptor antagonist","volume":"135","author":"Boyer","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s002100100463","article-title":"NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors","volume":"364","author":"Braun","year":"2001","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/1568026043451014","article-title":"Introduction: P2 receptors","volume":"4","author":"Burnstock","year":"2004","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib21","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE-Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib22","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1055\/s-2005-869522","article-title":"The P2 receptors and congenital platelet function defects","volume":"31","author":"Cattaneo","year":"2005","journal-title":"Semin Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib23","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1161\/01.ATV.19.10.2281","article-title":"ADP receptors and clinical bleeding disorders","volume":"19","author":"Cattaneo","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib24","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.V75.5.1081.1081","article-title":"Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates","volume":"75","author":"Cattaneo","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib25","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V80.11.2787.2787","article-title":"Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate","volume":"80","author":"Cattaneo","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib26","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1055\/s-0038-1656090","article-title":"Deficiency of (33P)2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production","volume":"77","author":"Cattaneo","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib27","doi-asserted-by":"crossref","first-page":"E101","DOI":"10.1161\/01.ATV.20.11.e101","article-title":"Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet \u2018primary secretion defect\u2019 are heterozygous for a defect of P2CYC receptors","volume":"20","author":"Cattaneo","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib28","first-page":"13","article-title":"New insights into the role of P2X1 in platelet function","volume":"87","author":"Cattaneo","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib29","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1073\/pnas.0437879100","article-title":"Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding","volume":"100","author":"Cattaneo","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib30","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.bcp.2004.06.026","article-title":"Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor","volume":"68","author":"Cattaneo","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib31","series-title":"Platelets in thrombotic and non-thrombotic disorders","first-page":"929","article-title":"Pharmacology of ticlopidine and clopidogrel","author":"Cazenave","year":"2002"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib32","doi-asserted-by":"crossref","first-page":"10775","DOI":"10.1074\/jbc.271.18.10775","article-title":"Phosphoinositide 3-kinase and p72syk noncovalently associate with the low affinity Fc gamma receptor on human platelets through an immunoreceptor tyrosine-based activation motif. Reconstitution with synthetic phosphopeptides","volume":"271","author":"Chacko","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib33","first-page":"250","article-title":"Cangrelor AstraZeneca","volume":"2","author":"Chattaraj","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib34","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1182\/blood.V91.9.3172","article-title":"The P2X1 receptor, an adenosine triphosphate-gated cation channel, is expressed in human platelets but not in human blood leukocytes","volume":"91","author":"Clifford","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0898-6568(00)00083-8","article-title":"Advances in signalling by extracellular nucleotides. the role and transduction mechanisms of P2Y receptors","volume":"12","author":"Communi","year":"2000","journal-title":"Cell Signal"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib36","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00062752-200309000-00002","article-title":"Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis","volume":"10","author":"Conley","year":"2003","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1476-5381.1982.tb09210.x","article-title":"Adenosine 5-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors","volume":"76","author":"Cusack","year":"1982","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib38","series-title":"Adenosine and Adenine Nucleotides as Regulators of Cellular Function","article-title":"Adenosine,adenine nucleotides, and platelet function","author":"Cusack","year":"1991"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0165-1838(00)00151-X","article-title":"Platelet P2 receptors: from curiosity to clinical targets","volume":"81","author":"Cusack","year":"2000","journal-title":"J Auton Nerv Syst"},{"issue":"A7","key":"10.1016\/j.pharmthera.2005.03.009_bib40","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0002-9149(00)01408-9","article-title":"Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting","volume":"87","author":"Dangas","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib41","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1074\/jbc.273.4.2024","article-title":"Molecular basis for ADP-induced platelet activation: I. Evidence for three distinct ADP receptors on human platelets","volume":"273","author":"Daniel","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib42","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI20986","article-title":"Central role of the P2Y12 receptor in platelet activation","volume":"113","author":"Dorsam","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib43","doi-asserted-by":"crossref","first-page":"47588","DOI":"10.1074\/jbc.M208778200","article-title":"Coordinated signaling through both G12\/13 and G(i) pathways is sufficient to activate GPIIb\/IIIa in human platelets","volume":"277","author":"Dorsam","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib44","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/10245330310001621260","article-title":"Clopidogrel: interactions with the P2Y12 receptor and clinical relevance","volume":"8","author":"Dorsam","year":"2003","journal-title":"Hematology"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib45","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1538-7836.2004.00692.x","article-title":"Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets","volume":"2","author":"Dorsam","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib46","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1055\/s-0037-1615655","article-title":"Differential involvement of the P2Y1 and P2YT receptors in the morphological changes of platelet aggregation","volume":"85","author":"Eckly","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib47","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/12447","article-title":"Targeted disruption of cd39\/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation","volume":"5","author":"Enjyoji","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib48","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/13522","article-title":"Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice","volume":"5","author":"Fabre","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.bjp.0701827","article-title":"P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors","volume":"124","author":"Fagura","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib50","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.CIR.0000085073.69189.88","article-title":"Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects","volume":"108","author":"Fontana","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib51","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1161\/01.CIR.0000106904.80795.35","article-title":"P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study","volume":"108","author":"Fontana","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib52","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI12242","article-title":"Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs","volume":"107","author":"Foster","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib53","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1055\/s-0038-1651643","article-title":"Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition","volume":"69","author":"Freund","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib54","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/192531a0","article-title":"Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets","volume":"192","author":"Gaarder","year":"1961","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib55","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-0037-1616220","article-title":"ADP receptors of platelets and their inhibition","volume":"86","author":"Gachet","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib56","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1055\/s-2005-869521","article-title":"The platelet P2 receptors in thrombosis","volume":"31","author":"Gachet","year":"2005","journal-title":"Semin Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib57","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1161\/01.ATV.19.8.2007","article-title":"Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel","volume":"19","author":"Geiger","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib58","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1182\/blood-2001-12-0284","article-title":"Effects of adenosine 5\u2032-diphosphate (ADP) receptor blockade on platelet aggregation under flow","volume":"99","author":"Goto","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib59","doi-asserted-by":"crossref","first-page":"24314","DOI":"10.1074\/jbc.273.38.24314","article-title":"Phosphatidylinositol 3,4,5-trisphosphate-dependent stimulation of phospholipase C-gamma2 is an early key event in FcgammaRIIA-mediated activation of human platelets","volume":"273","author":"Gratacap","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib60","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood.V96.10.3439","article-title":"FcgammaRIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation","volume":"96","author":"Gratacap","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib61","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2004-07-2893","article-title":"P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms","author":"Hardy","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib62","first-page":"333","article-title":"Interactions of the pharmacological receptors of blood platelets with adenylate cyclase","volume":"6","author":"Haslam","year":"1973","journal-title":"Ser Haematol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib63","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1073\/pnas.96.14.8120","article-title":"Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice","volume":"96","author":"Hauser","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib65","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1046\/j.1365-2141.1998.01056.x","article-title":"The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel","volume":"103","author":"Hechler","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib66","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.V92.1.152.413k27_152_159","article-title":"The P2Y1 receptor is necessary for adenosine 5\u2032-diphosphate-induced platelet aggregation","volume":"92","author":"Hechler","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib67","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1124\/mol.53.4.727","article-title":"ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor","volume":"53","author":"Hechler","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib68","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1084\/jem.20030144","article-title":"A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo","volume":"198","author":"Hechler","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib69","first-page":"18","article-title":"Effect of NF449, a novel selective P2X1 receptor antagonist, on platelet activation and thrombosis","author":"Hechler","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib64","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1055\/s-2005-869520","article-title":"The P2 receptors in platelet function","volume":"31","author":"Hechler","year":"2005","journal-title":"Semin Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib70","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.105.084673","article-title":"Inhibition of platelet functions and thrombosis through selective or non selective inhibition of the platelet P2 receptors with increasing doses of NF449","author":"Hechler","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib71","first-page":"1","article-title":"The adhesiveness of human blood platelets in vitro","volume":"12","author":"Hellem","year":"1960","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib72","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-2003-40669","article-title":"P2Y12, a new platelet ADP receptor, target of clopidogrel","volume":"3","author":"Herbert","year":"2003","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib73","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood.V80.9.2281.bloodjournal8092281","article-title":"Importance of platelets in experimental venous thrombosis in the rat","volume":"80","author":"Herbert","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib74","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1055\/s-0038-1651593","article-title":"Potentiating effect of clopidogrel and SR 46349, a novel 5-HT2 antagonist, on streptokinase-induced thrombolysis in the rabbit","volume":"69","author":"Herbert","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib75","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","article-title":"Identification of the platelet ADP receptor targeted by antithrombotic drugs","volume":"409","author":"Hollopeter","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib76","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1432-1033.1994.00021.x","article-title":"Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition","volume":"225","author":"Horstrup","year":"1994","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib77","first-page":"492","article-title":"Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model","volume":"295","author":"Huang","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(03)01761-8","article-title":"NF449, a novel picomolar potency antagonist at human P2X1 receptors","volume":"470","author":"Hulsmann","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib79","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1161\/01.ATV.16.12.1532","article-title":"Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation","volume":"16","author":"Humbert","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib80","first-page":"66","article-title":"Pharmacology of AR-C69931MX and related compounds: from pharmacological tools to clinical trials","volume":"85","author":"Humphries","year":"2000","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib81","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1021\/jm981072s","article-title":"Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy","volume":"42","author":"Ingall","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib82","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0149-2918(02)85149-9","article-title":"Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction","volume":"24","author":"Jacobsson","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib83","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-0037-1614427","article-title":"Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation","volume":"81","author":"Jantzen","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib84","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1074\/jbc.273.4.2030","article-title":"Molecular basis for ADP-induced platelet activation: II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets","volume":"273","author":"Jin","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib85","doi-asserted-by":"crossref","first-page":"8070","DOI":"10.1073\/pnas.95.14.8070","article-title":"Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation","volume":"95","author":"Jin","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib86","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ejmech.2004.01.007","article-title":"Structure\u2013activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist","volume":"39","author":"Kassack","year":"2004","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib87","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0014-5793(01)02824-1","article-title":"The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin-a phosphoinositide 3-kinase-dependent mechanism","volume":"505","author":"Kauffenstein","year":"2001","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib88","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1111\/j.1538-7836.2004.00926.x","article-title":"Adenine triphosphate nucleotides are antagonists at the P2Y12 receptor","volume":"2","author":"Kauffenstein","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib89","first-page":"107","article-title":"International union of pharmacology: XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits","volume":"53","author":"Khakh","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib90","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1021\/jm030127+","article-title":"2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists","volume":"46","author":"Kim","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib91","first-page":"707","article-title":"Mechanisms of platelet shape change, aggregation, and release induced by collagen, thrombin, or A23,187","volume":"90","author":"Kinlough-Rathbone","year":"1977","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib92","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2002-05-1533","article-title":"Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets","volume":"101","author":"Larson","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib93","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000047060.60595.CC","article-title":"Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug\u2013drug interaction","volume":"107","author":"Lau","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib94","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/01.CIR.0000112378.09325.F9","article-title":"Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance","volume":"109","author":"Lau","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib95","article-title":"The role of the P2Y1, P2Y12, and P2X1 platelet receptors in a laser induced model of arterial thrombosis in vivo","author":"Lenain","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib96","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1046\/j.1538-7836.2003.00144.x","article-title":"Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist","volume":"1","author":"Lenain","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib97","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0378-1119(96)00027-3","article-title":"Cloning and sequencing of a human cDNA encoding endothelial P2Y1 purinoceptor","volume":"171","author":"L\u00e9on","year":"1996","journal-title":"Gene"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib98","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0014-5793(97)00022-7","article-title":"The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells","volume":"403","author":"L\u00e9on","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib99","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1172\/JCI8399","article-title":"Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice","volume":"104","author":"L\u00e9on","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib100","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1055\/s-0037-1614570","article-title":"The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation","volume":"81","author":"L\u00e9on","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib101","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/01.CIR.103.5.718","article-title":"Key role of the P2Y(1) receptor in tissue factor-induced thrombin- dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist","volume":"103","author":"L\u00e9on","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib102","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1161\/01.ATV.0000092127.16125.E6","article-title":"Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity","volume":"23","author":"L\u00e9on","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib103","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood-2003-05-1385","article-title":"Platelet ADP receptors contribute to the initiation of intravascular coagulation","volume":"103","author":"L\u00e9on","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib104","doi-asserted-by":"crossref","first-page":"12009","DOI":"10.1074\/jbc.M111803200","article-title":"A Gi-dependent pathway is required for activation of the small GTPase Rap1B in human platelets","volume":"277","author":"Lova","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1074\/jbc.M204821200","article-title":"A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1B","volume":"278","author":"Lova","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib106","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1074\/jbc.271.6.2879","article-title":"Activation of receptor-operated cation channels via P2X1 not P2T purinoceptors in human platelets","volume":"271","author":"MacKenzie","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib107","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0038-1642759","article-title":"ADP plays a key role in thrombogenesis in rats","volume":"59","author":"Maffrand","year":"1988","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib108","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/sj.bjp.0703517","article-title":"ADP is not an agonist at P2X(1) receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets","volume":"131","author":"Mahaut-Smith","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib109","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/09537100410001682788","article-title":"Emerging roles for P2X1 receptors in platelet activation","volume":"15","author":"Mahaut-Smith","year":"2004","journal-title":"Platelets"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib110","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1538-7836.2004.00722.x","article-title":"The P2Y receptor plays an essential role in the platelet shape change induced by collagen when TxA2 formation is prevented","volume":"2","author":"Mangin","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib111","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1111\/j.1538-7836.2003.00479.x","article-title":"Heterologous cell\u2013cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1)","volume":"1","author":"Marcus","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib112","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE Study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib113","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/S0195-668X(03)00442-1","article-title":"Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function\u2014a flow cytometry study","volume":"24","author":"Neubauer","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib114","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood.V97.12.3829","article-title":"Evidence for cross-talk between glycoprotein VI and Gi-coupled receptors during collagen-induced platelet aggregation","volume":"97","author":"Nieswandt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib115","doi-asserted-by":"crossref","first-page":"39493","DOI":"10.1074\/jbc.M207256200","article-title":"Costimulation of Gi- and G12\/G13-mediated signaling pathways induces integrin alpha IIbbeta 3 activation in platelets","volume":"277","author":"Nieswandt","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib116","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/s-2005-869524","article-title":"Pharmacology of CS-747 (LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity","volume":"31","author":"Niitsu","year":"2005","journal-title":"Semin Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib117","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1161\/01.ATV.0000053387.06709.32","article-title":"Advantages of fast-acting ADP receptor blockade in ischemic heart disease","volume":"23","author":"Nurden","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib118","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1172\/JCI117835","article-title":"An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb\u2013IIIa complex function","volume":"95","author":"Nurden","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib119","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1042\/bj3120775","article-title":"The human platelet ADP receptor activates Gi2 proteins","volume":"312","author":"Ohlmann","year":"1995","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1055\/s-0038-1654542","article-title":"Macroscopic studies of platelet aggregation: nature of an aggregating factor in red blood cells and platelets","volume":"6","author":"Ollgard","year":"1961","journal-title":"Thromb Diath Haemorrh"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib121","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1055\/s-0037-1616060","article-title":"The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen","volume":"86","author":"Oury","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib122","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood-2002-03-0812","article-title":"P2X(1)-mediated activation of extracellular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen","volume":"100","author":"Oury","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib123","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1182\/blood-2002-10-3215","article-title":"Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype","volume":"101","author":"Oury","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib124","doi-asserted-by":"crossref","first-page":"26266","DOI":"10.1074\/jbc.M402032200","article-title":"ATP augments von Willebrand factor-dependent shear-induced platelet aggregation through Ca2+-calmodulin and myosin light chain kinase activation","volume":"279","author":"Oury","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib125","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1124\/mol.54.6.1118","article-title":"Agonist action of adenosine triphosphates at the human P2Y1 receptor","volume":"54","author":"Palmer","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib126","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/sj.bjp.0702690","article-title":"Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adnosine 5-diphosphate (ADP) in human platelets","volume":"127","author":"Park","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib127","article-title":"In vivo antiplatelet activity of a reversible P2Y12 receptor antagonist (abstract)","author":"Patel","year":"2004"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib128","first-page":"14","article-title":"Single dose pharmacokinetics and pharmacodynamics of AZD6140\u2014an oral reversible ADP receptor antagonist","volume":"89","author":"Peters","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib129","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/blood.V91.2.549","article-title":"Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation\/aggregation induced by sera from heparin-induced thrombocytopenia patients","volume":"91","author":"Polgar","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib130","first-page":"413","article-title":"Receptors for purines and pyrimidines","volume":"50","author":"Ralevic","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib131","series-title":"The Platelets: Physiology and Pharmacology","first-page":"85","article-title":"Adenine nucleotides in blood platelets","author":"Reimers","year":"1985"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib132","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/01.ATV.0000012805.49079.23","article-title":"Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood","volume":"22","author":"Remijn","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib133","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1055\/s-0037-1613243","article-title":"Effects of enhanced P2X1 receptor Ca2+ influx on functional responses in human platelets","volume":"88","author":"Rolf","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib134","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-0037-1615684","article-title":"Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP","volume":"85","author":"Rolf","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib135","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1182\/blood-2003-09-3040","article-title":"P2X1: definitely not an ADP receptor","volume":"102","author":"Rosa","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib136","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/nm1102-1227","article-title":"Platelets in atherothrombosis","volume":"8","author":"Ruggeri","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib137","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1074\/jbc.274.4.1898","article-title":"Fc receptor-mediated platelet activation is dependent on phosphatidylinositol 3-kinase activation and involves p120(Cbl)","volume":"274","author":"Saci","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib138","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-2005-869523","article-title":"Clopidogrel and ticlopidine: P2Y12 ADP-receptor antagonists for the prevention of atherothrombosis","volume":"31","author":"Savi","year":"2005","journal-title":"Semin Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib139","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00001721-199603000-00035","article-title":"cAMP is not an important messenger for ADP-induced platelet aggregation","volume":"7","author":"Savi","year":"1996","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib140","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1046\/j.1365-2141.1997.3133126.x","article-title":"Characterization of P2x1 purinoreceptors on rat platelets: effect of clopidogrel","volume":"98","author":"Savi","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib141","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0014-5793(98)00025-8","article-title":"Role of P2Y1 purinoceptor in ADP-induced platelet activation","volume":"422","author":"Savi","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib142","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel","volume":"84","author":"Savi","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib143","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1006\/bbrc.2001.4816","article-title":"P2y(12), a new platelet ADP receptor, target of clopidogrel","volume":"283","author":"Savi","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib144","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1006\/bbrc.1997.8001","article-title":"Identification of a P2X1 purinoceptor expressed on human platelets","volume":"242","author":"Scase","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib145","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1055\/s-0037-1614344","article-title":"Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets\u2014definition and detection of ticlopidine\/clopidogrel effects","volume":"82","author":"Schwarz","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib146","first-page":"665","article-title":"P2Y receptors: biological advances and therapeutic opportunities","volume":"4","author":"Shaver","year":"2001","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib147","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/sj.bjp.0703816","article-title":"Activity of adenosine diphosphates and triphosphates on a P2Y(T)-type receptor in brain capillary endothelial cells","volume":"132","author":"Simon","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib148","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib149","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1046\/j.1365-2141.2000.02208.x","article-title":"The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity","volume":"110","author":"Storey","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib150","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-0037-1615596","article-title":"Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes","volume":"85","author":"Storey","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib151","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/0953710021000024402","article-title":"Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease","volume":"13","author":"Storey","year":"2002","journal-title":"Platelets"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib152","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/sj.bjp.0703237","article-title":"The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties","volume":"129","author":"Sugidachi","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib153","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.bjp.0703761","article-title":"Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747","volume":"132","author":"Sugidachi","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib154","doi-asserted-by":"crossref","first-page":"11544","DOI":"10.1074\/jbc.273.19.11544","article-title":"P2X1 purinoceptor in human platelets. Molecular cloning and functional characterization after heterologous expression","volume":"273","author":"Sun","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib155","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0014-2999(99)00201-0","article-title":"No requirement of P2X1 purinoceptors for platelet aggregation","volume":"372","author":"Takano","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib156","first-page":"432","article-title":"Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor","volume":"60","author":"Takasaki","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib157","doi-asserted-by":"crossref","first-page":"46661","DOI":"10.1074\/jbc.M308452200","article-title":"P2X1-mediated ERK2 activation amplifies the collagen-induced platelet secretion by enhancing myosin light chain kinase activation","volume":"278","author":"Toth-Zsamboki","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib158","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/blood.V94.12.4156","article-title":"A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase","volume":"94","author":"Trumel","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib159","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1182\/blood.V98.12.3340","article-title":"Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow","volume":"98","author":"Turner","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib160","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.bjp.0704514","article-title":"Inhibition of adenylyl cyclase by neuronal P2Y receptors","volume":"135","author":"Unterberger","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib161","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/01.ATV.0000057809.32354.22","article-title":"In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability","volume":"23","author":"van Gestel","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib162","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1055\/s-0038-1665441","article-title":"Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines","volume":"78","author":"Vial","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib163","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1182\/blood-2003-06-1963","article-title":"Lack of evidence for functional ADP-activated human P2X1 receptors supports a role for ATP during hemostasis and thrombosis","volume":"102","author":"Vial","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib164","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/00004872-199917070-00022","article-title":"Compliance with aspirin or placebo in the hypertension optimal treatment (HOT) study","volume":"17","author":"Waeber","year":"1999","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib165","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1432-1033.1987.tb13357.x","article-title":"Vasodilator-stimulated protein phosphorylation in platelets is mediated by cAMP- and cGMP-dependent protein kinases","volume":"167","author":"Waldmann","year":"1987","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib166","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1124\/mol.65.2.426","article-title":"Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor","volume":"65","author":"Waldo","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib167","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.ATV.0000052669.50791.0B","article-title":"Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model","volume":"23","author":"Wang","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib168","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1538-7836.2003.00070.x","article-title":"Quantification of ADP and ATP receptor expression in human platelets","volume":"1","author":"Wang","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib169","doi-asserted-by":"crossref","first-page":"23382","DOI":"10.1074\/jbc.M202212200","article-title":"Activation of Rap1B by G(i) family members in platelets","volume":"277","author":"Woulfe","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/01.RES.70.1.39","article-title":"ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries","volume":"70","author":"Yao","year":"1992","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib171","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1161\/01.CIR.88.6.2888","article-title":"Combined ADP and thromboxane A2 antagonism prevents cyclic flow variations in stenosed and endothelium-injured arteries in nonhuman primates","volume":"88","author":"Yao","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib172","first-page":"H488","article-title":"Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis","volume":"267","author":"Yao","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib173","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib174","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2141.1982.tb01922.x","article-title":"Effect of ADP-utilizing enzymes on the arterial bleeding time in rats and rabbits","volume":"50","author":"Zawilska","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib175","doi-asserted-by":"crossref","first-page":"8608","DOI":"10.1074\/jbc.M009718200","article-title":"ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999","volume":"276","author":"Zhang","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2005.03.009_bib176","first-page":"19","article-title":"Studies of the specificity of the suramin analogue (NF449) as P2X1 receptor antagonist","author":"Zighetti","year":"2004","journal-title":"Haematologica"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725805000835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725805000835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T14:38:00Z","timestamp":1586270280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725805000835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":176,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S0163725805000835"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2005.03.009","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}